Rankings
▼
Calendar
TRDA Q1 2025 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TRDA
Entrada Therapeutics, Inc.
$502M
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$21M
-65.2% YoY
Gross Profit
$21M
100.0% margin
Operating Income
-$22M
-106.0% margin
Net Income
-$17M
-84.4% margin
EPS (Diluted)
$-0.42
QoQ Revenue Growth
-45.0%
Cash Flow
Operating Cash Flow
-$39M
Free Cash Flow
-$40M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$486M
Total Liabilities
$69M
Stockholders' Equity
$417M
Cash & Equivalents
$68M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$21M
$59M
-65.2%
Gross Profit
$21M
$59M
-65.2%
Operating Income
-$22M
$21M
-203.2%
Net Income
-$17M
$23M
-173.8%
Revenue Segments
License
$2M
100%
← FY 2025
All Quarters
Q2 2025 →